NDA Help Center

Login Dialog

Frequently Asked Questions


NDA Help Center

Filter Cart

The Filter Cart provides a powerful way to query and access data for which you may be interested.  

A few points related to the filter cart are important to understand with the NDA Query/Filter implementation: 

First, the filter cart is populated asyncronously.  So, when you run a query, it may take a moment to populate but this will happen in the background so you can define other queries during this time.  

When you are adding your first filter, all data associated with your query will be added to the filter cart (whether it be a collection, a concept, a study, a data structure/elment or subjects). Not all data structures or collections will necessarily be displayed.  For example, if you select the NDA imaging structure image03, and further restrict that query to scan_type fMRI, only fMRI images will appear and only the image03 structure will be shown.  To see other data structures, select "Find All Subject Data" which will query all data for those subjects. When a secord or third filter is applied, an AND condition is used.  A subject must exist in all filters.  If the subject does not appear in any one filter, that subjects data will not be included in your filter cart. If that happens, clear your filter cart, and start over.  

It is best to package more data than you need and access those data using other tools, independent of the NDA (e.g. miNDAR snapshot), to limit the data selected.  If you have any questions on data access, are interested in using avaialble web services, or need help accessing data, please contact us for assistance.  

Frequently Asked Questions



Reset Password

NDA provides a single access to de-identified autism research data. For permission to download data, you will need an NDA account with approved access to NDA or a connected repository (AGRE, IAN, or the ATP). For NDA access, you need to be a research investigator sponsored by an NIH recognized institution with federal wide assurance. See Request Access for more information.

Warning Notice

This is a U.S. Government computer system, which may be accessed and used only for authorized Government business by authorized personnel. Unauthorized access or use of this computer system may subject violators to criminal, civil, and/or administrative action. All information on this computer system may be intercepted, recorded, read, copied, and disclosed by and to authorized personnel for official purposes, including criminal investigations. Such information includes sensitive data encrypted to comply with confidentiality and privacy requirements. Access or use of this computer system by any person, whether authorized or unauthorized, constitutes consent to these terms. There is no right of privacy in this system.

Update Password

You have logged in with a temporary password. Please update your password. Passwords must contain 8 or more characters and must contain at least 3 of the following types of characters:

  • Uppercase
  • Lowercase
  • Numbers
  • Special Characters limited to: %,_,!,@,#,$,-,%,&,+,=,),(,*,^,:,;

Subscribe to our mailing list

Mailing List(s)
Email Format

You are now leaving the NIMH Data Archive (NDA) web site to go to:

Click on the address above if the page does not change within 10 seconds.


NDA is not responsible for the content of this external site and does not monitor other web sites for accuracy.

Accept Terms
Filter Cart
No filters selected
Value Range
Data Structures with shared data
No filters have been selected
Switch User

End of Phase Form



Clinical Trials: End of Phase Form

Download Definition as
Download Submission Template as
Element NameData TypeSizeRequiredDescriptionValue RangeNotesAliases
subjectkeyGUIDRequiredThe NDAR Global Unique Identifier (GUID) for research subjectNDAR*
src_subject_idString20RequiredSubject ID how it's defined in lab/projectCATIEID
interview_ageIntegerRequiredAge in months at the time of the interview/test/sampling/imaging.0 :: 1260Age is rounded to chronological month. If the research participant is 15-days-old at time of interview, the appropriate value would be 0 months. If the participant is 16-days-old, the value would be 1 month.
interview_dateDateRequiredDate on which the interview/genetic test/sampling/imaging/biospecimen was completed. MM/DD/YYYYRequired field
sexString20RequiredSex of the subjectM;FM = Male; F = Femalegender
visitidIntegerRecommendedMetaTrial Visit IDSystem variable: unique code for each type of visit -use to merge files
visitString50RecommendedVisit name
truncvisIntegerRecommendedTruncated Visit NumberCreated variable: provides a numeric visit number for all visits, including unscheduled and end of phase
phase_ctString20RecommendedCurrent Phase. Phase patient was in at the time of the assessment Phase 4 refers to the follow-up phase.Pre-Rand; Phase 1/1A; Phase 2; Phase 3; Phase 4; Phase 1B; Open-Choice Phase; Screening; Phase 1
visdayIntegerRecommendedNumber of days from study baseline to date of visit
protocolString50RecommendedProtocol [Study] name
rtd01IntegerRecommendedDay of phase discontinuationNumber of days from study baseline to date of phase discontinuationdayeop12, dayeop36
rtd02IntegerRecommendedDid pt successfully complete the medication0;10=No; 1=Yes, Skip to Section IV
rtd03IntegerRecommendedI.1 Administrative Discontinuation - Wer0;10=No;1= Yeseop03
rtd04IntegerRecommendedII. Clinical Discontinuation0;10=No;1= Yeseop04
rtd05aIntegerRecommendedInadequate therapeutic effect1;01=yes; 0=no
rtd05bIntegerRecommendedPlease choose1;21=Primary; 2=Secondary
rtd05cIntegerRecommendedThe problematc psychopatholgy was primarily1::41=Positive; 2=Negative; 3=Affective; 4=Other reason, specify
rtd06aIntegerRecommendedUnacceptable side effects0;10=No;1= Yes
rtd06bIntegerRecommendedPlease choose1;21=Primary; 2=Secondary
rtd06cIntegerRecommendedThe most problematic side effect was1::41=Extrapyramidal; 2=Weight/Metabolic; 3=Sexual; 4=Other reason, specify
rtd07aIntegerRecommendedRefusal/failure to take assigned antipsychotics0;10=No;1= Yes
rtd07cIntegerRecommendedIs patient agereable with taking diffrent antipsychotics?0;10=No;1= Yes
rtd08IntegerRecommendedPatient withdrawn by subject advocate0;10=No;1= Yes
rtd09IntegerRecommendedIs the pt proceeding to the next medicat0;10=No;1= Yes
rtd10IntegerRecommendedDid a substance use disorder contribute0;10=No;1= Yes
rtd11IntegerRecommendedCLINICIAN: Which medication do you think was used1::5;95;991=Olanzapine; 2=Quetiapine; 3=Risperidone; 4=Ziprasidone; 5=Perphenazine; 95=Refused to guess; 99=N/A On open-label Clozapine
rtd12IntegerRecommendedpt: Which medication do you think you were taken1::5;95;991=Olanzapine; 2=Quetiapine; 3=Risperidone; 4=Ziprasidone; 5=Perphenazine; 95=Refused to guess; 99=N/A On open-label Clozapine
rtd13IntegerRecommendedInvestigator signed end of phase source document0;10=No;1= Yes
rtd14IntegerRecommendedInvestigator faxed end of phase source document0;10=No;1= Yes
eop01IntegerRecommendedWhat phase is the patient being discontinued from?1;2;3;41=1; 2=2; 3=3; 4=Open Choicefhx10a
eop02aIntegerRecommendedDid the patient complete the full 36 weeks of study?0;10=No; 1=Yesfhx10b
eop04aIntegerRecommendedClinical Discontinuation: If yes, please state the reason1;2;3;4;51 = a. Inadequate therapeutic effect; 2 = b. Study drug was not sufficiently optim; 3 = c. Worsening of symptoms; 4 = d. Unacceptable side effects';' 5 = e. Study drug is no longer needed
eop04bIntegerRecommendedII. Clinical Discontinuation: The most problematic side effect was:1;2;3;4;5;6;71 = Extrapyramidal; 2 = Weight gain; 3 = Weight loss; 4 = Falling; 5 = Syncope/dizziness/vertigo; 6 = Confusion; 7 = Other reason
eop05IntegerRecommendedRefusal/failure to take the assigned study drug0;10=No; 1=Yes
eop05bIntegerRecommendedPatient Decision: Is the patient agreeable with taking a different study drug?0;10=No; 1=Yes
eop06IntegerRecommendedCaregiver's decision0;10=No; 1=Yes
eop06bIntegerRecommendedCaregiver's Decision: Is the caregiver agreeable with the patient taking a different study drug?0;10=No; 1=Yes
eop07IntegerRecommendedPatient died during this study phase0;10=No; 1=Yes
eop08IntegerRecommendedWhat is the course of action for the patient?1;2;31 = Move to next randomized phase; 2 = Move to open-choice phase; 3 = Discontinued from the study*
eop08aIntegerRecommendedCourse of Action: What randomized phase proceeding to?2;32=2; 3=3
eop09IntegerRecommendedHas the investigator signed the End of Phase source document?0;10=No; 1=Yes
eop02IntegerRecommendedDay of phase discontinuationNumber of days from study baseline to date of phase discontinuation
eop10IntegerRecommendedInvestigators Signature Day signed:Number of days from study baseline to date investigator's signature was obtained
eop07aIntegerRecommendedPatient Death: Day of patient deathNumber of days from study baseline to date of death
daylast1vstIntegerRecommendedstudy day of last TREATMENT visitdaylast2vst
complet1IntegerRecommendedDid this child complete Phase TREATMENT PORTION of the study?0;10 = no; 1 = yescomplet2
y1notdunIntegerRecommendedWhich one of the following explains why the subject did not complete Phase1::41 = Study dropout; 2 = Treatment dropout; 3 = Premature termination; 4 = Other reasony2notdun, y2notdun_d
lastp1wkIntegerRecommendedWeek of last TREATMENT visitlastp2wk
camsresponseIntegerRecommendedTREATMENT RESPONSE from End of Phase Form1;2;3;41 = Active Treatment Responder;2 = Active Treatment Non-responder;3 = Placebo Responder;4 = Placebo Non-responder
actvrespIntegerRecommendedActive Treatment responder: Does family agree to continue in maintenance treatment?0;10 = no; 1 = yes
nomaintxString50RecommendedActive Treatment responder: Explain no maintenance treatment
actvnonrIntegerRecommendedActive Treatment non-responder: Does family agree to community referral?0;10 = no; 1 = yes
nocomrefString50RecommendedActive Treatment non-responder: Explain no community referral
pborespIntegerRecommendedPlacebo responder: Does family agrees to monthly maintenance visits and IE assessments?0;10 = no; 1 = yes
nostoptxString50RecommendedPlacebo responder: Explain no maintenance and IE assessments
openlablIntegerRecommendedPlacebo non-responder: Does family agree to Open-label CAMS Treatment?0;10 = no; 1 = yes
treatment_nameString200Recommendedtreatment name
noopnlblString50RecommendedPlacebo non-responder: Explain no Open Label
faz1doneIntegerRecommendedDid child complete Phase Assessments?0;10 = no; 1 = yesfaz2done
completedIntegerRecommendedChecks if completed0::30=No; 1=Yes; 2=Yes, lost; 3=Unverifiedwk4
wkasscompIntegerRecommendedStudy Week Assessment Completed
faz2asmtIntegerRecommendedDoes the family agree to continue with Phase II Assessments?0;10 = no; 1 = yes
comments_miscString4,000RecommendedMiscellaneous comments on study, interview, methodology relevant to this form dataynofaz2
discontinuation_reason1String250RecommendedDiscontinuation Reason:otheresn
otheresn_dIntegerRecommendedOther Reason Derived1::51::5
final_r_pdIntegerRecommendedRemission Psychotic Depression: Remission was defined as a HAM-D 17 item score of 10 or lower at 2 consecutive assessments. Remission also required the absence of delusions (SADS delusional item score of 1) at the second remission of depression assessment. Subjects who were not delusional at both of 2 consecutive HAM-D assessments were considered remitted at both points; subjects who had been delusional at the first of the HAM-D assessments were considered to be remitted at the second assessment only, and subjects who were not delusional at the first assessment but had SADS scores higher than 1 at the second were classified as not remitted at either assessment. Subjects who achieved a HAM-D score of 10 or lower without delusions for the first time at week 12 were assessed again at week 13 to determine whether the 2-week duration criterion was met.0;10 = no; 1 = yes
lastvisitIntegerRecommendedThis variable indicates whether the assessment was the last for the subject. For the acute phase, this is generally at week 12, but the last weekly visit will vary for early terminators.0;10 = no; 1 = yes
outcome_textString100RecommendedOutcome Text
outcome_idIntegerRecommendedOutcome Code2::422 = Dropped Medical Reasons - Side Effects; 3 = Dropped Medical Reasons - Inter-current Events; 7 = No Longer Meets Study Criteria; 14 = Completed Study; 20 = Other; 21 = Death - non-suicide; 22 = Suicide attempt or increased suicidality; 23 = Worsening depression; 24 = Lost to follow-up; 25 = Patient moved - distance; 26 = Worsening psychosis; 27 = Worsening depression and psychosis; 28 = Other emergent psychiatric symptoms; 29 = Patient Perception: Clinical improvement; 30 = Completed suicide attempt; 34 = Patient perception: Ineffective treatment; 35 = Patient changed mind about participation in research; 36 = Patient's family opposed to his/her study participation; 37 = Patient refused further study med treatment (not due to side effects); 38 = Problems with transportation; 39 = Protocol violation; 41 = Inappropriate for research participation; 42 = Insufficient therapeutic response
outcomedaysIntegerRecommendedOutcome Days from Baseline
statusaIntegerRecommendedWhat was the outcome of the Acute Phase?1::31 = Met Full Remission criteria; 2 = Met Partial Remission criteria; 3 = Non-remitted; 4 = Randomized then exited
stabyesnoIntegerRecommendedFor Partial and Full Remitters at 12 weeks: Will patient enter Stabilization Phase?0;10 = no; 1 = yes
nostabexplainString500RecommendedExplain not going into Stabilization
study_idIntegerRecommendedStudy ID number46=Acute Phase; 47=Stabilization Phase
inttimewkIntegerRecommendedWeek of study: Initial-2 = pre-baseline (2 weeks); -1 = pre-baseline (1 week); 0 = baseline; 1 = week 1; 12 = week 12; 13 = week 13; 14 = week 14
weekFloatRecommendedWeek in level/study99=week 10-week 14intid
siteString101RecommendedSiteStudy Site
statussIntegerRecommendedWhat was the outcome of the Stabilization Phase?1::41 = Met Full Remission criteria; 2 = Met Partial Remission criteria; 3 = Relapse; 4 = Significant Clinical Worsening
responsibleIntegerRecommendedIf outcome is Early Termination, who was the primary person responsible for the early termination?1::51 = Patient; 2 = Study Investigator; 3 = Physician at institution- not involved in study; 4 = Physician outside institution (e.g., Primary care physician); 5 = Family member or significant other
Data Structure

This page displays the data structure defined for the measure identified in the title and structure short name. The table below displays a list of data elements in this structure (also called variables) and the following information:

  • Element Name: This is the standard element name
  • Data Type: Which type of data this element is, e.g. String, Float, File location.
  • Size: If applicable, the character limit of this element
  • Required: This column displays whether the element is Required for valid submissions, Recommended for valid submissions, Conditional on other elements, or Optional
  • Description: A basic description
  • Value Range: Which values can appear validly in this element (case sensitive for strings)
  • Notes: Expanded description or notes on coding of values
  • Aliases: A list of currently supported Aliases (alternate element names)
  • For valid elements with shared data, on the far left is a Filter button you can use to view a summary of shared data for that element and apply a query filter to your Cart based on selected value ranges

At the top of this page you can also:

  • Use the search bar to filter the elements displayed. This will not filter on the Size of Required columns
  • Download a copy of this definition in CSV format
  • Download a blank CSV submission template prepopulated with the correct structure header rows ready to fill with subject records and upload

Please email the The NDA Help Desk with any questions.

Distribution for DataStructure: endphase01 and Element:
Chart Help

Filters enable researchers to view the data shared in NDA before applying for access or for selecting specific data for download or NDA Study assignment. For those with access to NDA shared data, you may select specific values to be included by selecting an individual bar chart item or by selecting a range of values (e.g. interview_age) using the "Add Range" button. Note that not all elements have appropriately distinct values like comments and subjectkey and are not available for filtering. Additionally, item level detail is not always provided by the research community as indicated by the number of null values given.

Filters for multiple data elements within a structure are supported. Selections across multiple data structures will be supported in a future version of NDA.